Securities code: Shanghai Pharmaceuticals Holding Co.Ltd(601607) securities abbreviation: Shanghai Pharmaceuticals Holding Co.Ltd(601607) No.: pro 2022014
Shanghai Pharmaceuticals Holding Co.Ltd(601607)
Announcement on the reply to the notification letter on the preparations for the meeting of the issuance and Examination Committee of non-public offering of shares
The board of directors and all directors of the company guarantee that there are no false records, misleading statements or major omissions in the contents of this announcement, and bear individual and joint liabilities for the authenticity, accuracy and completeness of its contents.
Anxin Securities Co., Ltd. (hereinafter referred to as “Anxin securities”) is the sponsor of Shanghai Pharmaceuticals Holding Co.Ltd(601607) (hereinafter referred to as “the company”) non-public offering of A-Shares (hereinafter referred to as “this non-public offering”) in 2021, Recently, we received the letter on making preparations for the meeting of the stock issuance and Examination Committee of Shanghai Pharmaceuticals Holding Co.Ltd(601607) non-public Development Bank (hereinafter referred to as the “notification letter”) issued by the issuance and supervision department of the China Securities Regulatory Commission (hereinafter referred to as the “CSRC”).
The company has conducted serious supplementary investigation and verification with Anson securities and other relevant intermediaries on the issues raised in the notification letter, made reply explanations on relevant issues one by one, and publicly disclosed the reply to the notification letter. For details, please refer to the website of Shanghai Stock Exchange on the same day（ http://www.sse.com.cn./ ）Reply of Shanghai Pharmaceuticals Holding Co.Ltd(601607) Co., Ltd. and Anxin Securities Co., Ltd. to the letter on please make preparations for the meeting of the non-public development bank stock issuance and Examination Committee of Shanghai Pharmaceuticals Holding Co.Ltd(601607) Co., Ltd. Meanwhile, the company will submit the reply materials of the notification letter to the CSRC as required.
The company’s non-public offering still needs to be approved by the CSRC, and whether it can be approved is still uncertain. The company will fulfill the obligation of information disclosure in time according to the review progress of the matter by the CSRC. Please pay attention to the investment risks.
It is hereby announced.
Shanghai Pharmaceuticals Holding Co.Ltd(601607)
Board of directors
March 8, 2022
